Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)

NCT00981838 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Nephrotic Syndrome

Interventions

DRUG: Rituximab

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]